Synthorx (Synthorx) Debt-to-Asset : 0.02 (As of Sep. 2019)

View and export this data going back to 2018. Start your Free Trial

What is Synthorx Debt-to-Asset?

Synthorx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $0.50 Mil. Synthorx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $3.35 Mil. Synthorx's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2019 was $163.67 Mil. Synthorx's debt to asset for the quarter that ended in Sep. 2019 was 0.02.

Synthorx Debt-to-Asset Historical Data

The historical data trend for Synthorx's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthorx Debt-to-Asset Chart

Synthorx Annual Data

Trend

Dec16

Dec17

Dec18

Debt-to-Asset

Synthorx Quarterly Data
	Dec16	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Debt-to-Asset	Get a 7-Day Free Trial				-	-	0.02	0.02	0.02

Competitive Comparison of Synthorx's Debt-to-Asset

For the Biotechnology subindustry, Synthorx's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synthorx's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthorx's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Synthorx's Debt-to-Asset falls into.

Synthorx Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Synthorx's Debt-to-Asset for the fiscal year that ended in Dec. 2018 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	191.506
	=	0.00

Synthorx's Debt-to-Asset for the quarter that ended in Sep. 2019 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.502	+	3.351)	/	163.671
	=	0.02

Synthorx (NAS:THOR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Synthorx Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Synthorx's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Synthorx (Synthorx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037

Website

http://www.synthorx.com

Executives

Powell Andrew Kenneth William	director	C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver	director, officer: President and CEO	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022